2024-11-07  5:29:57 PM Chg. +0.50 Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
52.20EUR +0.97% 11,264
Turnover: 615,119.23
-Bid Size: - -Ask Size: - 10.72 bill.EUR 2.31% 27.50

Business description

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange, with a total staff of around 4,000, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey, in North Africa and in the United States of America. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties within the urogenital therapeutic area and of treatments for rare diseases.
 

Management board & Supervisory board

CEO
Robert Koremans
Management board
Andrea Recordati, Giampiero Mazza, Guido Guidi, Joanna Le Couilliard, Michaela Castelli, Piergiorgio Peluso, Cathrin Petty, Giorgio De Palma, Elisa Corghi, Luigi La Corte, Kim Stratton
Supervisory board
Antonio Santi, Andrea Balelli, Ezio Simonelli, Livia Amidani Aliberti, Patrizia Oriundi Paleologo, Emiliano Nitti , Marco Antonio Viganò
 

Company data

Name: Recordati S.p.A.
Address: via M. Civitali 1,I-20148 Milano
Phone: +39-02-48787-1
Fax: +39-02-40073-747
E-mail: -
Internet: www.recordati.com/
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12-31
Free Float: 46.40%
IPO date: 1984-01-01

Investor relations

Name: Marianne Tatschke
IR phone: -
IR Fax: +39-02-48787-225
IR e-mail: inver@recordati.it

Company calendar

CW 45 | 2024-11-08 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

CVC Capital Partners
 
51.80%
Others
 
48.20%